Abiopharma

BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Reports the reporting period Financial Results BLACK DIAMOND THERAPEUTICS, INC. (BDTX) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 70000
• Net Income: (0.16)
• EPS: Not disclosed
• Cash and equivalents: 118258
  • In April 2026, Black Diamond announced the following presentations at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago: ◦May 30, 2026, 1:15 PM
  • 2:45 PM CDT: Oral presentation on updated clinical data from the Phase 2 trial in patients with non
  • classical EGFRm NSCLC in the frontline setting, including preliminary duration of response (DOR) and progression
    • targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995